TG Therapeutics, Inc. TGTX
57.43
(0.09)
(0.16%)
as of 25 Sep
- Market cap
- $8.8B
- P/E
- 18.9×
Follow TGTX
Growth Flags
show if company had growth for consecutive years
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 100.28% | 112.60% | 102.75% | 111.96% |
+8 more TTM periods Free account |
|
| 37.70% | 42.27% | 54.50% | 55.55% | ||
ROIC |
10.69% | 11.48% | 10.25% | 8.91% | |
Return on Tangible Assets |
50.33% | 51.33% | 93.75% | 101.02% | |
Average Days of Receivables |
183.32 | 204.32 | 181.01 | 182.11 | |
Free Cash Flow per Share |
0.12 | (0.10) | (0.17) | (0.48) | |
Free Cash Flow |
17.39 | (14.19) | (24.99) | (70.24) | |
Capital Expenditures |
(0.49) | (0.24) | (0.21) | (0.17) | |
Piotroski F-Score |
4.00 | 3.00 | 4.00 | 4.00 | |
| Other line items | |||||
Cash ROIC |
0.94% | (0.76%) | (2.39%) | (7.12%) | |
Accounts Receivable Turnover |
2.53 | 2.41 | 2.83 | 2.79 | |
Accounts Payable Turnover |
0.81 | 0.84 | 1.21 | 0.73 | |
Inventory Turnover |
0.93 | 0.83 | 0.85 | 0.67 | |
Average Days of Payables |
553.42 | 457.76 | 389.62 | 525.86 | |
Days of Inventory on Hand |
383.22 | 396.82 | 455.14 | 687.91 | |
Tax Rate |
3.35 | 2.78 | 3.16 | 4.10 | |
Research and Development Expense of Revenue |
28.05% | 22.95% | 26.00% | 26.24% | |
Selling, General and Administrative Expense of Revenue |
37.27% | 38.76% | 37.65% | 39.78% | |
Share Based Compensation of Revenue |
10.15% | 9.94% | 10.49% | 11.46% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.04 | (0.03) | (0.06) | (0.16) | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
1.42 | 0.18 | 0.09 | 0.05 | |
Revenue per Share |
5.64 | 4.85 | 4.27 | 3.66 | |
Operating CF per Share |
0.13 | (0.10) | (0.17) | (0.48) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
55.22% | 65.95% | 72.56% | 84.13% |
Columns are period end dates